[Cardiovascular action of aldosterone].
Miyamori
Isamu
I
Third Department of Internal Medicine, University of Fukui, Faculty of Medical Sciences.
Kawai
Yasuyuki
Y
Fan
Chun Yuan
CY
D000450:Aldosterone / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology*; D004730:Endothelium, Vascular / Q000187:drug effects; D053503:Epithelial Sodium Channels; D000077545:Eplerenone; D005355:Fibrosis; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009206:Myocardium / Q000473:pathology; D018384:Oxidative Stress; D018161:Receptors, Mineralocorticoid / Q000502:physiology; D015222:Sodium Channels / Q000378:metabolism; D012982:Sodium, Dietary / Q000009:adverse effects; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use
D053503:Epithelial Sodium Channels; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D015222:Sodium Channels; D012982:Sodium, Dietary; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D000254:Sodium-Potassium-Exchanging ATPase